login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
VISTAGEN THERAPEUTICS INC (VTGN) Stock News
NASDAQ:VTGN -
US92840H4002
-
Common Stock
3.17
USD
+0.11 (+3.59%)
Last: 8/22/2025, 8:00:02 PM
3.23
USD
+0.06 (+1.89%)
After Hours:
8/22/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VTGN Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: The Motley Fool
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
16 days ago - By: Zacks Investment Research
- Mentions:
MRSN
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
16 days ago - By: Vistagen
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
16 days ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
17 days ago - By: Zacks Investment Research
- Mentions:
EXAS
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
17 days ago - By: Benzinga
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings
18 days ago - By: Zacks Investment Research
- Mentions:
INO
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
23 days ago - By: Vistagen
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
a month ago - By: Vistagen
Vistagen to Present at the BTIG Virtual Biotechnology Conference
a month ago - By: Vistagen
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
2 months ago - By: Yahoo Finance
- Mentions:
XTIA
XTI Aerospace Plans 4.5 Million Share Offering With Warrants
2 months ago - By: Yahoo Finance
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay
2 months ago - By: Vistagen
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
2 months ago - By: Vistagen
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
2 months ago - By: Vistagen
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
3 months ago - By: Vistagen
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
3 months ago - By: Vistagen
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
3 months ago - By: Vistagen
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
3 months ago - By: Zacks Investment Research
- Mentions:
IRD
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
CLSD
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
4 months ago - By: Vistagen
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
5 months ago - By: Vistagen
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
6 months ago - By: Vistagen
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
6 months ago - By: Vistagen
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
6 months ago - By: Vistagen
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
7 months ago - By: Vistagen
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
7 months ago - By: Vistagen
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
7 months ago - By: Vistagen
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
8 months ago - By: Vistagen
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
9 months ago - By: Vistagen
Vistagen to Present at the Stifel 2024 Healthcare Conference
10 months ago - By: Vistagen
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
10 months ago - By: Vistagen
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
10 months ago - By: Vistagen
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
11 months ago - By: Vistagen
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
a year ago - By: Vistagen
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
a year ago - By: Invezz
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
Please enable JavaScript to continue using this application.